J Vialard

847 total citations
11 papers, 700 citations indexed

About

J Vialard is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, J Vialard has authored 11 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in J Vialard's work include Viral Infectious Diseases and Gene Expression in Insects (3 papers), Insect Resistance and Genetics (3 papers) and DNA Repair Mechanisms (2 papers). J Vialard is often cited by papers focused on Viral Infectious Diseases and Gene Expression in Insects (3 papers), Insect Resistance and Genetics (3 papers) and DNA Repair Mechanisms (2 papers). J Vialard collaborates with scholars based in Canada, France and Belgium. J Vialard's co-authors include Christopher D. Richardson, Ghalib Alkhatib, D Henning, C. Richardson, Manon Lalumière, Thierry Vernet, Dalius J. Briedis, David B. Levin, Francis Fabre and María Ángeles de la Torre-Ruiz and has published in prestigious journals such as The EMBO Journal, Oncogene and Journal of Virology.

In The Last Decade

J Vialard

11 papers receiving 682 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J Vialard Canada 10 610 108 95 82 82 11 700
Germán Rosas-Acosta United States 15 819 1.3× 157 1.5× 46 0.5× 69 0.8× 126 1.5× 26 947
Jan A. van der Knaap Netherlands 13 871 1.4× 101 0.9× 93 1.0× 37 0.5× 92 1.1× 17 1.0k
P. Elaine Butler United Kingdom 6 292 0.5× 122 1.1× 132 1.4× 89 1.1× 42 0.5× 10 564
Sarah L. Irons United Kingdom 11 539 0.9× 32 0.3× 115 1.2× 73 0.9× 29 0.4× 19 710
Vida Puizdar Slovenia 12 345 0.6× 65 0.6× 102 1.1× 53 0.6× 19 0.2× 19 476
Ruth E. Hanna United States 11 1.0k 1.7× 156 1.4× 77 0.8× 35 0.4× 166 2.0× 13 1.2k
Christine Strand United States 7 819 1.3× 128 1.2× 62 0.7× 32 0.4× 146 1.8× 7 995
Mary C. Thomas United States 10 841 1.4× 179 1.7× 73 0.8× 24 0.3× 152 1.9× 11 1.1k
Paul A. Aeed United States 11 302 0.5× 80 0.7× 51 0.5× 51 0.6× 21 0.3× 17 532
Tracy Nissan Sweden 17 1.2k 2.0× 89 0.8× 93 1.0× 38 0.5× 79 1.0× 25 1.3k

Countries citing papers authored by J Vialard

Since Specialization
Citations

This map shows the geographic impact of J Vialard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Vialard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Vialard more than expected).

Fields of papers citing papers by J Vialard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Vialard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Vialard. The network helps show where J Vialard may publish in the future.

Co-authorship network of co-authors of J Vialard

This figure shows the co-authorship network connecting the top 25 collaborators of J Vialard. A scholar is included among the top collaborators of J Vialard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Vialard. J Vialard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Terranova, Nadia, Kim Stuyckens, Anne‐Gaëlle Dosne, et al.. (2021). A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib. Cancer Chemotherapy and Pharmacology. 89(1). 117–128. 10 indexed citations
2.
Querolle, Olivier, Valério Berdini, Gordon Saxty, et al.. (2014). 356 Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinity. European Journal of Cancer. 50. 115–115. 1 indexed citations
3.
Dun, Jacky Van, Thierry Grand‐Perret, Stefanie De Schepper, et al.. (2006). Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells. Oncogene. 25(50). 6672–6677. 21 indexed citations
4.
Vermeulen, Linda, et al.. (2004). Involvement of GSK-3 beta in TWEAK-mediated NF-kappa B activation. Ghent University Academic Bibliography (Ghent University). 10 indexed citations
6.
Aboussekhra, Abdelilah, et al.. (1996). A novel role for the budding yeast RAD9 checkpoint gene in DNA damage-dependent transcription.. The EMBO Journal. 15(15). 3912–3922. 102 indexed citations
8.
Vialard, J, et al.. (1992). [Experimental paratuberculosis in sheep after intravenous or oral inoculation: pathogenicity and biologic diagnosis].. PubMed. 23(2). 105–15. 10 indexed citations
9.
Vialard, J, Manon Lalumière, Thierry Vernet, et al.. (1990). Synthesis of the membrane fusion and hemagglutinin proteins of measles virus, using a novel baculovirus vector containing the beta-galactosidase gene. Journal of Virology. 64(1). 37–50. 215 indexed citations
10.
Vialard, J, Lilly Yuen, & Christopher D. Richardson. (1990). Identification and characterization of a baculovirus occlusion body glycoprotein which resembles spheroidin, an entomopoxvirus protein. Journal of Virology. 64(12). 5804–5811. 30 indexed citations
11.
Lerondelle, Catherine, et al.. (1989). [The mammary gland: target organ for infection with the caprine arthritis and encephalitis virus].. PubMed. 20(1). 57–63. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026